The drug nimorazole belongs to a class of chemicals known as 5-nitroimidazoles. Drugs from this class are used against infection. In addition, nimorazole makes tumour cells more sensitive to radiotherapy.
Therefore, the investigators want to find out whether the addition of nimorazole to the standard treatment with radiotherapy in combination with chemotherapy with cisplatin shows activity against Locally Advanced Head and Neck HPV Negative Squamous Cell Cancers and is safe.
Furthermore, the investigators will investigate if a specific examination done with tumour tissue will help to predict whether the treatment will work or not.
Trans Tasman Radiation Oncology Group (TROG), Danish Head and Neck Cancer Group (DAHANCA)
Closing Date of Accrual
Professor Sandro Porceddu, Princess Alexandra Hospital, QLD
After a hiatus from in-person events due to COVID-19
The RAVES trial treating prostate cancer Participating in a
For over 30 years, TROG Cancer Research has been dedicated to improving the way radiation medicine is delivered to cancer patients with ongoing scientific research, clinical trials, and cutting-edge technology.
Keep up to date with TROG news, subscribe to our community newsletter.